Profitability
Weight: 15%
F
0
- 5yr Avg ROIC -9.7%
- Operating Margin Trend -149.71 pp/yr
JANX
Janux Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 21.2 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -12.8%
- 5yr Share-Count CAGR 8.3%
Growth Quality
Weight: 35%
D+
40
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -595.9%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 13.29
Stability
Weight: 5%
D
33
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 1
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 2 added.
- Holders
- 2
- Avg Δ position
- +543.4%
- New buys
- 0
- Full exits
- 0